Fluicell
Fluicell is a Swedish life science company focused on microfluidic technologies for cell handling, tissue production, and regenerative medicine applications. Its business centers on the Nexocyte platform and related technologies used to build tissue-based research models and therapeutic concepts, including work in type 1 diabetes.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueTools and platforms for precise cell handling, patterning, and tissue construction.
R&D programs aimed at tissue-based therapeutic applications and translational development.
Partnered development work and project-based scientific support for external collaborators.
Customers
Fluicell sells primarily to research and development partners rather than mass-market end users. Its customers and collaborators include academic researchers, biotech and medtech organizations, and clinical or translational partners working on cell therapy and tissue engineering. The company’s offerings are used when customers need specialized microfluidic control, tissue model creation, or disease-focused regenerative medicine development.
Buy microfluidic tools and tissue-production capabilities for experimental and preclinical research.
Use the platform in collaborative development programs for tissue engineering and regenerative medicine.
Engage in disease-specific programs, including type 1 diabetes tissue-based therapy work.
Strategy
Fluicell’s strategy is centered on advancing its two main project areas: the Nexocyte technology platform and regenerative medicine applications. The company is also building external collaborations, including work in type 1 diabetes, to convert its scientific platform into repeatable commercial and development relationships.
A platform approach can support multiple applications and recurring collaboration opportunities.
Therapeutic applications can create higher-value development partnerships and future product pathways.
External partners provide scientific validation, materials, and commercialization leverage.
Geography
Fluicell is headquartered in Sweden and operates as a Nordic life science company with international research collaboration potential. The business is not tied to a single end market geography because its technologies can be used in global research and development programs, but its operating base and reporting are Swedish.
Risks
Fluicell’s business depends on successful scientific development, partner execution, and the ability to convert platform technology into commercial value. As a small R&D-driven company, it also faces funding, dilution, and execution risk, while regulatory and translational uncertainty can delay or prevent therapeutic applications from reaching the market.
- Financing and dilution riskImpact: HighLikelihood: High
Development-stage life science companies often need external capital before revenues scale.
Exposure: Equity-funded operations
- Regulatory and translational riskImpact: HighLikelihood: High
Therapeutic applications require successful preclinical and clinical progression before commercialization.
Exposure: Regenerative medicine and tissue-based therapies
- Research and development failureImpact: High
The company’s value depends on proving that its microfluidic and tissue-production technologies work in practice.
Exposure: Nexocyte and regenerative medicine programs
- Partner and collaboration dependenceImpact: Medium
Projects rely on external collaborators for know-how, materials, and validation.
Exposure: Type 1 diabetes collaboration and other development programs
Accounting
Judgemental itemsCollaboration income may depend on milestones, deliverables, or service completion timing.
Impact: Can create quarter-to-quarter volatility in reported revenue
Most development costs are likely expensed as incurred in a life science R&D model.
Impact: Directly affects operating loss and cash burn
Scientific programs may not reach commercialization, requiring write-downs.
Impact: Can materially affect earnings and equity
Large changes in share count can distort per-share comparability.
Impact: Affects EPS and investor interpretation of performance
Similar listed companies
Publicly listed companies with a comparable business focus.
NewcelX Ltd.
NCEL · Pharmaceutical Preparations
Vericel Corp
VCEL · Biological Products, (No Diagnostic Substances)
Vericel Corp is a U.S.-based biopharmaceutical company focused on advanced therapies for cartilage repair and severe burn care.
Stimcell Energetics Inc.
STME · Surgical & Medical Instruments & Apparatus
CellaVision
CEVI · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Cryo-Cell International, Inc
CCEL · Services-Misc Health & Allied Services, NEC
Cryo-Cell International is a U.S.-based cellular processing and cryogenic storage company focused on preserving umbilical cord blood and cord tissue stem cells…
MaxCyte, Inc
MXCT · Services-Commercial Physical & Biological Research
MaxCyte is a cell-engineering tools and platform company built around its Flow Electroporation technology and ExPERT instrument family.
Last updated: 24/09/2026